Literature DB >> 22614240

A click chemistry route to 2-functionalised PEGylated and cationic β-cyclodextrins: co-formulation opportunities for siRNA delivery.

Aoife M O'Mahony1, Julien Ogier, Stephane Desgranges, John F Cryan, Raphael Darcy, Caitriona M O'Driscoll.   

Abstract

A new approach to the synthesis of amphiphilic β-cyclodextrins has used 'click' chemistry to selectively modify the secondary 2-hydroxyl group. The resulting extended polar groups can be either polycationic or neutral PEGylated groups and these two amphiphile classes are compatible in dual cyclodextrin formulations for delivery of siRNA. When used alone with an siRNA, a cationic cyclodextrin was shown to have good transfection properties in cell culture. Co-formulation with a PEGylated cyclodextrin altered the physicochemical properties of nanoparticles formed with siRNA. Improved particle properties included lower surface charges and reduced tendency to aggregate. However, as expected, the transfection efficiency of the cationic vector was lowered by co-formulation with the PEGylated cyclodextrin, requiring future surface modification of particles with targeting ligands for effective siRNA delivery.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22614240     DOI: 10.1039/c2ob25490e

Source DB:  PubMed          Journal:  Org Biomol Chem        ISSN: 1477-0520            Impact factor:   3.876


  11 in total

1.  Facile synthesis of per(6-O-tert-butyldimethylsilyl)-α-, β-, and γ-cyclodextrin as protected intermediates for the functionalization of the secondary face of the macrocycles.

Authors:  Gábor Benkovics; Milo Malanga; Giovanna Cutrone; Szabolcs Béni; Antonio Vargas-Berenguel; Juan Manuel Casas-Solvas
Journal:  Nat Protoc       Date:  2021-01-15       Impact factor: 13.491

2.  Cyclodextrin mediated delivery of NF-κB and SRF siRNA reduces the invasion potential of prostate cancer cells in vitro.

Authors:  J C Evans; J McCarthy; C Torres-Fuentes; J F Cryan; J Ogier; R Darcy; R W Watson; C M O'Driscoll
Journal:  Gene Ther       Date:  2015-05-25       Impact factor: 5.250

3.  Cyclodextrins in drug delivery: applications in gene and combination therapy.

Authors:  Rebecca M Haley; Riccardo Gottardi; Robert Langer; Michael J Mitchell
Journal:  Drug Deliv Transl Res       Date:  2020-06       Impact factor: 4.617

4.  Click-modified cyclodextrins as nonviral vectors for neuronal siRNA delivery.

Authors:  A M O'Mahony; B M D C Godinho; J Ogier; M Devocelle; R Darcy; J F Cryan; C M O'Driscoll
Journal:  ACS Chem Neurosci       Date:  2012-08-03       Impact factor: 4.418

5.  In vitro investigations of the efficacy of cyclodextrin-siRNA complexes modified with lipid-PEG-Octaarginine: towards a formulation strategy for non-viral neuronal siRNA delivery.

Authors:  Aoife M O'Mahony; Stephane Desgranges; Julien Ogier; Aoife Quinlan; Marc Devocelle; Raphael Darcy; John F Cryan; Caitriona M O'Driscoll
Journal:  Pharm Res       Date:  2012-11-29       Impact factor: 4.200

6.  Cationic and PEGylated Amphiphilic Cyclodextrins: Co-Formulation Opportunities for Neuronal Sirna Delivery.

Authors:  Aoife M O'Mahony; Julien Ogier; Raphael Darcy; John F Cryan; Caitriona M O'Driscoll
Journal:  PLoS One       Date:  2013-06-21       Impact factor: 3.240

Review 7.  RNA interference-based nanosystems for inflammatory bowel disease therapy.

Authors:  Jian Guo; Xiaojing Jiang; Shuangying Gui
Journal:  Int J Nanomedicine       Date:  2016-10-12

Review 8.  Gene delivery based on macrocyclic amphiphiles.

Authors:  Wen-Chao Geng; Qiaoxian Huang; Zhe Xu; Ruibing Wang; Dong-Sheng Guo
Journal:  Theranostics       Date:  2019-05-18       Impact factor: 11.556

9.  Modulating Polymer-siRNA Binding Does Not Promote Polyplex-Mediated Silencing.

Authors:  R Chauncey Splichal; Joseph A Gredell; Erin B Vogel; Amanda Malefyt; Georgina Comiskey; Milton R Smith; Christina Chan; S Patrick Walton
Journal:  Nucleic Acid Ther       Date:  2020-07-29       Impact factor: 4.244

Review 10.  Review: Local Tumor Necrosis Factor-α Inhibition in Inflammatory Bowel Disease.

Authors:  Bahez Gareb; Antonius T Otten; Henderik W Frijlink; Gerard Dijkstra; Jos G W Kosterink
Journal:  Pharmaceutics       Date:  2020-06-11       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.